✦ LIBER ✦

A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance

✍ Scribed by Masakazu Toi, Toshiaki Saeki, Hiroji Iwata, Kenichi Inoue, Yutaka Tokuda…

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination of docetaxel and TSU-68, an

✍ Kim, Sung-Bae; Yoo, Changhoon; Ro, Jungsil; Im, Seock-Ah; Im, Young-Hyuck; Kim, 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 486 KB

A multicenter phase II study of TSU-68,

✍ Suzuki, Yasuhiro; Saeki, Toshiaki; Aogi, Kenjiro; Toi, Masakazu; Fujii, Hirofumi 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 259 KB

5058 POSTER Randomized Phase II Multicen

✍ Kim, S.; Ahn, J.H.; Ro, J.; Im, S.A.; Im, Y.H.; Kim, J.H.; Song, H.S.; Kang, S.Y 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

A phase II study of weekly docetaxel in

✍ Hugo E. R. Ford; Yoon-Sim Yap; David W. Miles; Andreas Makris; Marcia Hall; Liz 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 311 KB

348 A phase II trial of docetaxel in pat

✍ J.P. Guastalla; J. Bonneterre; P. Fumoleau; M. Piccart; M. Tubiana; B. Chevallie 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 269 KB

Bortezomib/docetaxel combination therapy

✍ Awada, A; Albanell, J; Canney, P A; Dirix, L Y; Gil, T; Cardoso, F; Gascon, P; P 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 162 KB